Ozanimod therapy in COVID-19 patients requiring oxygen support: a randomized, open label, pilot trial
Description
BACKGROUND: Sphingosine-1-phosphate receptor ligands (SRLs) dampen immunopathological damages in models of viral pneumonia.
